{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:02:16Z","timestamp":1777525336935,"version":"3.51.4"},"reference-count":26,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz. J. Biol."],"abstract":"<jats:p>Abstract The current COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) poses a threat to global health owing to its high rate of spread and severe forms of respiratory infection. The lack of vaccines and antivirals prevents clinical strategies against the disease, creating an emerging need for the development of safe and effective treatments. Strategies for vaccine development include complete vaccines against viruses, subunits, and nucleic acids, but are still in their early stages. Studies carried out to date on possible SARS-CoV2 drug targets highlight glycoprotein S, Mpro (main protease or protease type 3C), and a member of the transmembrane serine protease II families (TMPRSS2). However, due to the pandemic state, priority is given to marketed drugs. These include chloroquine (CQ), hydroxychloroquine (HCQ), nitazoxanide, remdesivir, Lopinavir\/ritonavir (LPV \/ r), in addition to treatment with convalescent plasma. But, therapeutic specific effects against SARS-CoV2 have not yet been verified. Most of the information obtained about treatment is based on preliminary and limited studies. We conclude that, at this time of emergency, the search for new therapies is more urgent due to the need to save lives. Thus, we point out as interesting targets for future more specific research: glycoprotein S, Mpro, and TMPRSS2.<\/jats:p>","DOI":"10.1590\/1519-6984.238155","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T04:55:08Z","timestamp":1591851308000},"page":"698-701","source":"Crossref","is-referenced-by-count":12,"title":["Fighting COVID-19"],"prefix":"10.1590","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-3018","authenticated-orcid":false,"given":"D. M. O.","family":"Campos","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio Grande do Norte,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-7678","authenticated-orcid":false,"given":"C. B. S.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Hospital Pedi\u00e1trico Maria Alice Fernandes,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-2420","authenticated-orcid":false,"given":"J. M. A.","family":"Andrade","sequence":"additional","affiliation":[{"name":"Hemocentro Dalton Cunh,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-921X","authenticated-orcid":false,"given":"J. I. N.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Norte,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2020,9]]},"reference":[{"issue":"19","key":"ref1","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"Trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"CAO B.A.","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"CHAN J.F.W.","year":"2015","journal-title":"The Journal of Infectious Diseases"},{"key":"ref3","article-title":"Efficacies of lopinavir\/ritonavir and abidol in the treatment of novel coronavirus pneumonia","volume":"38","author":"CHEN J.","year":"2020","journal-title":"Chinese Journal of Infectious Disease"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"CHEN L.","year":"2020","journal-title":"The Lancet. Infectious Diseases"},{"key":"ref5","first-page":"1","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","author":"CHEN W.","year":"2020","journal-title":"Current Tropical Medicine Reports"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"CHU C.M.","year":"2004","journal-title":"Thorax"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"DONG L.","year":"2020","journal-title":"Drug Discoveries & Therapeutics"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01533-w","article-title":"Q&A: the novel coronavirus outbreak causing COVID-19","volume":"18","author":"FISHER D.","year":"2020","journal-title":"BMC Medicine"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciz100","article-title":"Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness","volume":"69","author":"GAMI\u00d1O-ARROYO A.E.","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"GAO J.","year":"2020","journal-title":"Bioscience Trends"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"GAUTRET P.","year":"2020","journal-title":"International Journal of Antimicrobial Agents"},{"key":"ref12","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"GREIN J.","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"10224","key":"ref13","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0140-6736(20)30374-3","article-title":"COVID-19: what is next for public health?","volume":"395","author":"HEYMANN D.L.","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"HOFFMANN M.","year":"2020","journal-title":"Cell"},{"issue":"1","key":"ref15","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"JUN C.H.E.N.","year":"2020","journal-title":"Journal of Zhe Jiang University"},{"key":"ref16","first-page":"369","article-title":"Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence","volume":"369","author":"LENZER J.","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"ref17","first-page":"1","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"LIU J.","year":"2020","journal-title":"Cell Discovery"},{"key":"ref18","first-page":"1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","author":"LONG Q.X.","year":"2020","journal-title":"Nature Medicine"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/JVI.02322-09","article-title":"Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae","volume":"84","author":"O\u2019KEEFE B.","year":"2010","journal-title":"Journal of Virology"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"ROSSIGNOL J.F.","year":"2016","journal-title":"Journal of Infection and Public Health"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"WALLS A.C.","year":"2020","journal-title":"Cell"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"WANG M.","year":"2020","journal-title":"Cell Research"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"WANG Z.","year":"2020","journal-title":"Bioscience Trends"},{"key":"ref24","article-title":"Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation","author":"XU Z.","year":"2020","journal-title":"bioRxiv"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"YAMAMOTO M.","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref26","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","author":"ZHOU D.","year":"2020","journal-title":"The Journal of Antimicrobial Chemotherapy"}],"container-title":["Brazilian Journal of Biology"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjb\/v80n3\/1519-6984-bjb-1519-6984238155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T23:50:45Z","timestamp":1611445845000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1519-69842020000300698&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["S1519-69842020000300698"],"URL":"https:\/\/doi.org\/10.1590\/1519-6984.238155","relation":{},"ISSN":["1678-4375","1519-6984"],"issn-type":[{"value":"1678-4375","type":"electronic"},{"value":"1519-6984","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}